GenScript Biotech Reports Robust Growth in 2024
GenScript Biotech sees 43.5% revenue rise, expanding global reach and strengthening pipeline.
- Latest
- Trending
GenScript Biotech sees 43.5% revenue rise, expanding global reach and strengthening pipeline.
European biotech set to soar with digital tech aiding sustainable innovations and industrial processes.
Dan Morehead notes a political shift towards pro-crypto due to changing voter demographics and economic policies.
Exploring AstraZeneca's strategic investments in digital health to enhance R&D, patient care, and partnerships.
Biotech firms restructure with layoffs as FDA approves new drugs, exemplifying industry challenges and opportunities.
Cassava Sciences stands out as a leading debt-free stock with significant upside potential, offering strong financial health.
Tecan reports lower H1 2024 sales, revises full-year outlook due to biopharma sector weakness and market challenges in China.
Federal push to harness AI in medical research relies on extensive data collection and privacy safeguards.
David Millette sues Nvidia for unjust enrichment, claiming AI video use without compensation, weeks after suing OpenAI.
AI-designed proteins transform with molecular switches, paving new paths in biotechnology innovation and drug delivery.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.